177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).

ABSTRACT:

Purpose

Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data on this modality have been published regarding large samples treated in everyday practice.

Methods

We analyzed prospectively collected registry data regarding lutetium-177 (¹⁷⁷Lu)-PSMA-617 RLT of 254 consecutive men with mCRPC seen in everyday academic practice. Since ¹⁷⁷Lu-PSMA-617 was experimental salvage treatment following failure of individually appropriate conventional therapies, patients were generally elderly and heavily pretreated (median age 70 year

SUBMITTER: Khreish F 

PROVIDER: S-EPMC8803625 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature